Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales

Last updated: January 24, 2024
Sponsor: University of Plymouth
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cerebral Palsy

Learning Disorders

Mental Disability

Treatment

N/A

Clinical Study ID

NCT06238089
4548
331470
TRUST/VC/AC/SG/6328-9580
  • Ages > 18
  • All Genders

Study Summary

The overall aim of this observational study is to establish the anti-psychotic prescribing patterns across specialist intellectual disability (ID) services in England and Wales by collecting cross-sectional retrospective data at 7 annual time-points (1st July) from 2017 to 2023.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient had psychiatric review by specialist adult ID services in the last year (e.g.for a patient to be included at 1st June 2017, data to be recorded from the mostrecent psychiatric review within the period between 1st January 2017 - 31st December 2017).
  • Patient has a diagnosis of ID
  • Patient under the care of specialist adult ID services
  • Patient on >2 anti-psychotic treatments (oral and IM injectable (depots))

Exclusion

Exclusion Criteria:

  • Patients treated with Clozapine
  • Under the age of 18 years

Study Design

Total Participants: 600
Study Start date:
December 19, 2023
Estimated Completion Date:
April 30, 2024

Study Description

Feasibility protocol objectives:

  1. Is it feasible to identify People with Intellectual Disabilities (PwID) who have been prescribed 2 or more anti-psychotic medications over 7 years retrospectively.

  2. It is possible to obtain a complete data set for each patient identified and therefore be able to explore the prescribing patterns across the eight sites.

  3. Is it feasible to quantify anti-psychotic treatment (APT) prescribing in PwID as chlorpromazine equivalent dose values across different healthcare Trusts in England and Wales.

    Main objectives:

  4. To explore yearly and overall prescribing patterns among PwID (with or without mental-health reasons (psychiatric co-morbidities)) in receipt of ≥2 forms of anti-psychotic treatment (multiple) over time?

  5. How has multiple anti-psychotic treatment prescribing changed between 2017 and 2023 using chlorpromazine equivalent dose values, in PwID with mental health and no mental health indications?

  6. What has been the impact of the COVID-19 pandemic (and corresponding lockdown restrictions in England and Wales) on multiple anti-psychotic treatment prescribing among PwID?

  7. Can the NHS England Statistical Process Control tool (SPC) be utilised to track yearly anti-psychotic treatment prescribing among PwID receiving multiple forms of anti-psychotic treatment, and monitor variation between services (sites) and patient groups (e.g. psychiatric co-morbidities; challenging behaviour).

Connect with a study center

  • Cheshire and Wirral Partnership NHS Foundation Trust

    Chester,
    United Kingdom

    Active - Recruiting

  • Coventry and Warwickshire Partnership NHS Trust

    Coventry,
    United Kingdom

    Site Not Available

  • Hertfordshire Partnership University NHS Foundation Trust

    Hatfield,
    United Kingdom

    Site Not Available

  • Leicestershire Partnership NHS Trust

    Leicester,
    United Kingdom

    Active - Recruiting

  • Central and North West London NHS Foundation Trust

    London,
    United Kingdom

    Active - Recruiting

  • North East London NHS Foundation Trust

    London,
    United Kingdom

    Site Not Available

  • Cornwall Partnership NHS Foundation Trust

    Redruth,
    United Kingdom

    Site Not Available

  • Swansea Bay University Health Board

    Swansea,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.